Biosimilar Newsletter Archive
-
09.29.22 -- EMA Releases Statement Supporting Biosimilar Interchangeability In EU
9/29/2022
09/29/22 Biosimilar Development Newsletter
-
09.22.22 -- A CTO's Journey Into Continuous Biomanufacturing
9/22/2022
09/22/22 Biosimilar Development Newsletter
-
09.16.22 -- How Updated FDA Guidance Impacts Component Selection
9/16/2022
09/16/22 Biosimilar Development Newsletter
-
09.15.22 -- De-Risking Biosimilar Development With A Suitable Autoinjector
9/15/2022
09/15/22 Biosimilar Development Newsletter
-
09.14.22 -- Biopharma Leaders Address Resilient Biomanufacturing Capacity Needs
9/14/2022
09/14/22 Biosimilar Development Newsletter
-
09.12.22 -- How Biopharma Leaders Are Pursuing Funding, Advocacy, And Regulatory Convergence
9/12/2022
09/12/22 Biosimilar Development Newsletter
-
09.08.22 -- Listen Now: Vaxxinity's Biologic Revolution, Best Practices for Partnering with a CDMO, and more!
9/8/2022
09/08/22 Biosimilar Development Newsletter
-
09.08.22 -- FDA Seeks Comments on Remote Regulatory Assessments
9/8/2022
09/08/22 Biosimilar Development Newsletter
-
09.07.22 -- A Guide To CDMO Selection
9/7/2022
09/07/22 Biosimilar Development Newsletter
-
09.01.22 -- Liposomal And Nanoparticle Technology At Pfizer Melbourne
9/1/2022
09/01/22 Biosimilar Development Newsletter
This website uses cookies to ensure you get the best experience on our website. Learn more